Leap Therapeutics Q2 2024 GAAP EPS $(0.52) Misses $(0.43) Estimate, Cash And Cash Equivalents Totaled $78.5M At June 30, 2024, Expected To Fund Leap's Operating And Capital Expenditures Into Q2 Of 2026
Portfolio Pulse from Benzinga Newsdesk
Leap Therapeutics reported a Q2 2024 GAAP EPS of $(0.52), missing the estimate of $(0.43). The company has $78.5M in cash and cash equivalents as of June 30, 2024, which is expected to fund its operations and capital expenditures into Q2 2026.
August 12, 2024 | 11:25 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Leap Therapeutics reported a Q2 2024 GAAP EPS of $(0.52), missing the estimate of $(0.43). The company has $78.5M in cash and cash equivalents as of June 30, 2024, which is expected to fund its operations and capital expenditures into Q2 2026.
The EPS miss is a negative indicator for the stock price in the short term. However, the company's strong cash position provides some reassurance about its financial stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100